Valneva SE ADR Dossier - Source-backed chat

Valneva SE ADR

VLAEuronext Paris

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.25

Intrinsic Value $10.89median of 2 methodsbased on filings through 31 Dec 2025

Market Price $6.18Price as of 30 Sep 2026

Significantly undervaluedIntrinsic value is 76% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+76%)

Data confidence Sign in to view data confidence

Market Cap $586.5M

Enterprise Value $684.1M

Shares Outstanding 168.2M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Valneva SE is a specialty vaccine company transitioning through a critical operational pivot. While the company faced a major setback with the voluntary US withdrawal of its chikungunya vaccine IXCHIQ due to safety investigations, its long-term investment case is heavily anchored by its 6-valent Lyme disease vaccine candidate, PF-07307405 (LB6V), partnered with Pfizer. The candidate demonstrated a clinically meaningful 73.2% efficacy in its Phase 3 VALOR trial. Although the trial missed its primary statistical criterion due to lower-than-expected disease incidence, Pfizer's commitment to proceed with global regulatory submissions provides a strong catalyst. Concurrently, Valneva's aggressive restructuring plan to slash operating expenses by 25% to 35% and reduce its global workforce by 10% to 15% is expected to significantly lower its cash burn and extend its financial runway.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.80

Mean target$12.20

High · most bullish analyst$18.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Regulatory authorities reject or delay the approval of the Lyme disease vaccine candidate due to the Phase 3 trial missing its primary statistical endpoint. Geopolitical tensions continue to depress travel vaccine demand, and restructuring fails to offset the high cash burn, forcing dilutive capital raises.

Base CaseCentral scenario

Pfizer successfully submits regulatory filings for the Lyme disease vaccine candidate PF-07307405 (LB6V) in late 2026 or early 2027. Valneva's restructuring efforts successfully reduce operating expenses by 25% to 35%, narrowing net losses. Travel vaccine sales stabilize within the revised guidance of €135 million to €150 million despite geopolitical headwinds.

Bull CaseUpside scenario

Valneva's bull case centers on its late-stage vaccine pipeline, highlighted by VLA15, the only Phase 3 Lyme disease vaccine candidate in advanced clinical development (partnered with Pfizer), targeting a potential $1 billion-plus market. Additionally, the company is driving growth through its commercial travel vaccine portfolio (IXIARO and DUKORAL), expanding global access to its single-dose chikungunya vaccine IXCHIQ (approved in Europe, Canada, the UK, and Brazil), and advancing its clinically advanced Shigella vaccine candidate (S4V). Strategic restructuring efforts aiming for a 25%-35% reduction in operating expenses, combined with potential milestone payments and royalties from VLA15, position the company for potential sustained profitability starting in 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong Phase 3 efficacy of 73.2% for the partnered Lyme disease vaccine candidate (PF-07307405), which addresses a massive unmet medical need with no current human vaccines on the market.
Strategic partnership with Pfizer, which mitigates development costs and provides robust global commercialization capabilities.
Aggressive cost-restructuring program targeting a 25% to 35% reduction in operating expenses to preserve cash runway.

Key Investment Risks

Regulatory risk associated with PF-07307405 after the Phase 3 VALOR trial missed its primary pre-specified statistical endpoint.
Commercial and reputational fallout from the voluntary US withdrawal of the chikungunya vaccine IXCHIQ following FDA safety investigations.
Geopolitical headwinds impacting travel vaccine uptake, which forced a downward revision of 2026 sales guidance.

Thesis Invalidation Triggers

Refusal of the FDA or EMA to file or review the regulatory submissions for the Lyme disease vaccine candidate PF-07307405.
Emergence of new serious adverse events (SAEs) in international markets that compromise the safety profile of IXCHIQ or other commercial products.
Failure to achieve the targeted 25% to 35% reduction in operating expenses, leading to a severe cash runway crisis.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.